Mobinul Injection
Negotiable Min Order Quantity Unit
- Required Quantity
-
- Place of Origin
- Payment Terms
- Negotiable
- Production method
- Negotiable
- Shipping / Lead Time
- Negotiable / Negotiable
- Keyword
- Category
- Pharmaceuticals
Myungmoon Pharm. Co., Ltd.
- Country / Year Established
-
South Korea
/
- Business type
- Others
- Verified Certificate
-
16
| Product name | Mobinul Injection | Certification | - |
|---|---|---|---|
| Category | Pharmaceuticals | Ingredients | - |
| Keyword | - | Unit Size | - |
| Brand name | - | Unit Weigh | - |
| origin | Stock | - | |
| Supply type | - | HS code | - |
Product Information
Package :1ml/Amp x 50
Composition
- Glycopyrrolate 0.2mg
Dosage & Administration
- Adults : Intramuscular, intravenously, preoperative 0.02ml/kg by intramuscular injection. Mobinul injection may be used during surgery. It should be administration intravenously as single doese of 0.5mg and repeated, as needed at intervals of 2∼3minutes.
- Mobinul injection 1ml may be combined with each 1.0mg of neostigmine or 5.0ml of pyridostigmine.
- In the case of peptic ulcer, Mobinul injection is 0.5ml administered at 4 hours intervals, 3∼4 times daily by subcutaneously, intramusculary, intravenously.
Indication & Usage
- For use as a preoperative antimuscarine to reduce salivary, tracheobronchial, and pharyngeal secretions, to reduce the volume and free acidity of gastric secretions, and to block cardiac vagal inhibitory reflexes
- For protect against the peripheral muscarinic effects(e,g., bradycardia and excessive secretion) of cholinergic agents such as neostigmine and pyridostigmine
- Anticholinergic effect in peptic ulcer : adjunctive therapy for peptic ulce
B2B Trade
| Price (FOB) | Negotiable | transportation | - |
|---|---|---|---|
| MOQ | Negotiable | Leadtime | Negotiable |
| Payment Options | Negotiable | Shipping time | Negotiable |
- President
- LEE, GYU HUOK
- Address
- Myungmoon B/D, 946-18, Dokok-Dong, Gangnam-Ku, Korea
- Product Category
- Beauty & Personal Care,Chemical & Pharmaceutical Machinery,Pharmaceuticals
- No. of Total Employees
- 101-500
- Company introduction
-
In 1983, Myungmoon Pharm. Co., Ltd. was established for the improvement of national health. It is achieving remarkable development via research and development, production, and sales based on its founding principle: Advancement, Harmony, and Creation. Myungmoon Pharm. Co., Ltd. is an acknowledged manufacturer to produce the finished medicines; Injection, Tablet, Capsule, Patches, Solution and Creams.
Nowadays, Myungmoon Pharm. Co., Ltd. produces more than 250 specialized and general medicines and has more than 400 specialized and generalmedicine licenses to be able to manufacture. Myungmoon Pharm. Co., Ltd. is focusing on our research and development efforts so that Myungmoon Pharm. Co., Ltd. is launching more than 20 new products every year.
Myungmoon Pharm. Co., Ltd. established the new plant for API in 2008. Myungmoon Pharm. Co., Ltd has Gabapentin(USP) and the other 8 API products now, however, Myungmoon Pharm. Co., Ltd. would have many new API products in the foreseeable future. To gain a foothold on biomedicine products, outsourcing strategies are preceding the use of trusted clinical agency CRO and production agency CMO, and Myungmoon Pharm. Co., Ltd has already started to develop human growth hormones through a bio-venture corporation. Within 2 or 3 years, Myungmoon Pharm. Co., Ltd. should be launching bio-similar, including EPO and the processing of the complement of plants for biomedical products as well as the development of advanced medical bioethics, including monoclonal antibodies.
Myungmoon Pharm. Co., Ltd. is sharply developing to be a professional and global treatment company in the world.
- Main Markets
-
China
- Main Product
_2.jpg "Sentrip Oral Dissolving Film 10mg_20mg_Treatment for Erectile dysfunction__1")
